Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy

NCT07555301 · tracked via the Priya Life Science Switzerland tracker

Sponsor

Waid City Hospital, Zurich

Phase

Observational

Started

2026-06-01

Last updated

2026-04-29

Condition(s) studied

IgA Nephropathy (IgAN)

Investigational drug(s) / intervention(s)

sparsentan →sparsentan →

sparsentan: Follow up observation of patients with IgA Nephropathy on sparsentan regarding Albuminuria and GFR

sparsentan: follow up observation of Albuminuria and GFR in IgA patients in therapy with sparsentan

Study summary

An observational study tracking the clinical course of patients with IgA nephropathy.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * IgA Nephropathy, Use of Sparsentan Exclusion Criteria: * age \< 18y

Primary outcome measure(s)

Change of Albuminuria — 36 months
What is the impact of sparsentan on Albuminuria

Trial sites (1)

Facility	City	Region	Status
Stadtspital Zurich	Zurich	Canton of Zurich

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07555301 on ClinicalTrials.gov ↗ ← All trials in Switzerland